Showing 4241-4250 of 7767 results for "".
- Almirall's Tildrakizumab Demonstrates Meaningful Sleep Improvement in People Living with Psoriasishttps://practicaldermatology.com/news/almiralls-tildrakizumab-demonstrates-meaningful-sleep-improvement-in-people-living-with-psoriasis/2461345/During the 31st EADV (European Association of Dermatology and Venereology) Congress, Almirall S.A shared the results from TRIBUTE, an interventional phase IV clinical study that resembled real-life clinical practice. In this study, Ilumetri (tildrakizumab) is&n
- Cutera: Aviclear Hits 1,000 Treatment Markhttps://practicaldermatology.com/news/cutera-aviclear-hits-1000-treatment-mark/2461333/More than 1,000 AviClear laser acne treatments have been performed in the United States, Cutera reports. AviClear is FDA-cleared for the treatment of mild, moderate and severe acne. Additionally, AviClear recently received approval from Health Canada for the treatment of all severities
- Game On: IFPA Launches the “Explore Psoriatic Disease Together” Campaign to Build the IFPA Island on Animal Crossing: New Horizonshttps://practicaldermatology.com/news/game-on-ifpa-launches-the-explore-psoriatic-disease-together-campaign-to-build-the-ifpa-island-on-animal-crossing-new-horizons/2461328/The International Federation of Psoriatic Disease Associations (IFPA) is launching a campaign to build the IFPA Island on the Nintendo video game, Animal Crossing: New Horizons. This new campaign is called “Explore Psoriatic Disease Together” and calls on the psoriatic disea
- Boehringer Ingelheim's Spevigo Is first Treatment FDA-Approved for GPPhttps://practicaldermatology.com/news/boehringer-ingelheims-spevigo-is-first-treatment-fda-approved-for-gpp/2461327/FDA has approved Spevigo (spesolimab) from Boehringer Ingelheim as the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spevigo is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signali
- FDA Nod for Revelle Aesthetics, Inc's Avéli for Long-Term Reduction in Cellulitehttps://practicaldermatology.com/news/fda-nod-for-revelle-aesthetics-incs-aveli-for-long-term-reduction-in-cellulite/2461325/Revelle Aesthetics, Inc. scored an extended FDA clearance for Avéli. Avéli is now indicated for long-term reduction in the appearance of cellulite in the buttocks and thigh areas of adult females, demonstrating benefits through one year. "For far too l
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCChttps://practicaldermatology.com/news/sirnaomics-achieves-100-complete-response-in-phase-ii-clinical-trial-of-stp705-for-treatment-of-cutaneous-bcc/2461319/Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports. STP705 is a siRNA (small inte
- Tecovirimat Safe and Effective for Treating Skin Lesions of Monkeypoxhttps://practicaldermatology.com/news/tecovirimat-safe-and-effective-for-treating-skin-lesions-of-monkeypox/2461318/The antiviral tecovirimat appears to be safe and effective for the treatment of monkeypox symptoms and skin lesions, according to a research letter published in JAMA. The study is one of the ea
- Study: Colorescience Total Eye Firm & Repair Cream Improves Appearance of Overall Periorbital Areahttps://practicaldermatology.com/news/study-colorescience-total-eye-firm-repair-cream-improves-appearance-of-overall-periorbital-area/2461316/Colorescience Total Eye Firm & Repair Cream improves periorbital wrinkles, dryness, laxity and dark circles, according to a study in the Journal of Cosmetic Dermatology. Results of the clinical study
- First Patient Dosed in Phase 1b/2 Trial of Dermaliq Therapeutics's DLQ02 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-1b2-trial-of-dermaliq-therapeuticss-dlq02-for-pso/2461310/The first patient has been dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor, Dermaliq Therapeutics, Inc. reports. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaqu
- Pulsed-Dye Laser Reduces the Effects of Hypertrophic Scars Post-thyroidectomyhttps://practicaldermatology.com/news/pulsed-dye-laser-reduces-the-effects-of-hypertrophic-scars-post-thyroidectomy/2461308/Treatment with a 595 nm pulsed dye laser (PDL) can prevent and improve hypertrophic scars in patients with post-thyroidectomy in a cost-effective fashion, a new study shows. For the study, 19 patients with hypertrophic scars after thyroidectomy underwent